Your browser is no longer supported. Please, upgrade your browser.
Settings
PTN Palatin Technologies, Inc. daily Stock Chart
PTN [AMEX]
Palatin Technologies, Inc.
Index- P/E3.89 EPS (ttm)0.14 Insider Own7.70% Shs Outstand235.32M Perf Week-2.88%
Market Cap130.70M Forward P/E- EPS next Y-0.08 Insider Trans0.00% Shs Float218.79M Perf Month5.68%
Income37.10M PEG- EPS next Q-0.02 Inst Own23.50% Short Float5.06% Perf Quarter22.83%
Sales60.40M P/S2.16 EPS this Y40.90% Inst Trans-0.42% Short Ratio4.03 Perf Half Y-10.47%
Book/sh0.37 P/B1.51 EPS next Y11.10% ROA38.50% Target Price- Perf Year-38.20%
Cash/sh0.38 P/C1.47 EPS next 5Y- ROE39.60% 52W Range0.35 - 1.13 Perf YTD-28.41%
Dividend- P/FCF3.24 EPS past 5Y26.70% ROI35.50% 52W High-50.57% Beta1.54
Dividend %- Quick Ratio26.70 Sales past 5Y- Gross Margin- 52W Low57.75% ATR0.03
Employees18 Current Ratio26.70 Sales Q/Q- Oper. Margin- RSI (14)45.01 Volatility3.53% 6.59%
OptionableNo Debt/Eq0.00 EPS Q/Q17.30% Profit Margin61.40% Rel Volume0.44 Prev Close0.57
ShortableYes LT Debt/Eq0.00 EarningsMay 12 BMO Payout0.00% Avg Volume2.74M Price0.56
Recom1.30 SMA20-0.95% SMA500.02% SMA200-7.68% Volume1,206,616 Change-1.79%
Jun-05-15Reiterated Canaccord Genuity Buy $4 → $6
Jan-12-15Reiterated ROTH Capital Buy $6 → $4
May-23-12Initiated Noble Financial Buy
Jan-23-07Initiated Next Generation Buy $5
Jul-14-20 01:19PM  
Jul-08-20 07:30AM  
Jun-29-20 07:30AM  
Jun-23-20 04:54PM  
02:38PM  
08:05AM  
07:30AM  
Jun-05-20 03:14PM  
May-14-20 07:02PM  
May-13-20 03:01AM  
May-12-20 07:30AM  
Apr-30-20 07:30AM  
Mar-28-20 10:28AM  
Mar-03-20 12:56PM  
Feb-21-20 10:22AM  
Feb-19-20 07:30AM  
Feb-11-20 07:30AM  
Feb-06-20 07:30AM  
Jan-21-20 07:30AM  
Jan-16-20 08:36AM  
Dec-20-19 05:13PM  
Dec-11-19 11:43AM  
Dec-03-19 11:44PM  
Nov-13-19 07:30AM  
Nov-07-19 07:30AM  
Oct-31-19 11:53AM  
Oct-17-19 07:00AM  
Oct-16-19 07:00AM  
Oct-08-19 02:06PM  
Sep-17-19 05:41PM  
08:42AM  
Sep-12-19 07:30AM  
Sep-11-19 12:00PM  
Aug-19-19 10:44AM  
Aug-16-19 10:42AM  
Aug-13-19 05:45PM  
Aug-06-19 09:30AM  
07:00AM  
Jul-26-19 05:45PM  
Jul-19-19 05:45PM  
Jul-17-19 09:30AM  
Jul-12-19 12:51PM  
Jul-01-19 07:00AM  
Jun-25-19 03:49PM  
Jun-24-19 04:45PM  
04:19PM  
10:54AM  
08:03AM  
Jun-21-19 05:41PM  
05:40PM  
05:13PM  
Jun-06-19 07:30AM  
May-20-19 03:48PM  
May-14-19 08:17AM  
May-10-19 01:23PM  
May-09-19 09:00AM  
07:30AM  
May-03-19 04:30PM  
Apr-15-19 09:27AM  
Apr-05-19 10:46AM  
Apr-04-19 07:30AM  
Mar-02-19 08:34AM  
Feb-26-19 07:40AM  
Feb-12-19 05:20PM  
07:30AM  
Feb-06-19 07:30AM  
Dec-30-18 03:27PM  
Dec-18-18 12:06PM  
Dec-07-18 02:20PM  
Nov-27-18 07:40AM  
Nov-17-18 08:08AM  
Nov-13-18 08:11AM  
07:30AM  
Nov-11-18 08:51AM  
Nov-08-18 07:30AM  
Nov-07-18 04:15PM  
Nov-05-18 10:30AM  
Oct-12-18 07:55AM  
Sep-18-18 10:33PM  
Sep-13-18 08:01AM  
07:30AM  
07:08AM  
Sep-07-18 04:00PM  
Sep-02-18 09:41AM  
Aug-10-18 07:30AM  
Jul-17-18 07:30AM  
Jun-25-18 04:56PM  
08:05AM  
Jun-06-18 07:30AM  
Jun-04-18 08:03AM  
07:10AM  
May-29-18 04:53AM  
May-22-18 09:53PM  
May-15-18 07:30AM  
07:23AM  
May-10-18 04:30PM  
08:10AM  
May-09-18 07:30AM  
May-06-18 10:02AM  
Apr-19-18 11:50AM  
Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific product candidates for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist, which has completed Phase III trial for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor 1 (MCr) agonist peptide that has completed Phase I clinical trial for inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease. Further, it is involved in developing MC4r agonist peptide and small molecule for the treatment of rare genetic metabolic and obesity disorders. Additionally, the company engages in the development of PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.